Medivation Gets $110M Upfront From Astellas In Prostate Cancer Collaboration

Medivation has been here before and apparently likes the terrain. In a deal similar to last year's partnership with Pfizer on Dimebon, the company announced on Oct. 27 that it will receive a $110 million upfront payment to collaborate with Astellas on the development and commercialization of its Phase III prostate cancer candidate MDV3100

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip